The invention relates to a blood treatment device having at least one metering line which opens into a fluid circuit, wherein a conveyor module is arranged in the metering line and comprises a membrane pump and a valve which is arranged at the pressure side thereof and which can act both as a blocking valve and as a restricting valve.

The invention relates to a membrane pump device 2 for conveying fluids, in particular medical liquids for blood treatment. The invention furthermore relates to a membrane pump with a membrane pump device 2 and an actuating device 1 for the membrane pump device 2. The membrane pump device 2 has a pump chamber body 253 in which a recess, which is closed by an elastic membrane 201 to form a pump chamber 252, is constructed. The membrane pump device 2 moreover comprises an inward flow path 219 which connects an entry connection 204 to an inlet opening 215 of the pump chamber 252, and an outward flow path 223 which connects an outlet opening 216 of the pump chamber 252 to an exit connection 205. An inlet valve 202 is provided in the inward flow path 219 and an outlet valve 203 is provided in the outward flow path 223. The outlet valve 203 is a membrane valve which has a valve body 254A in which a recess is constructed which is closed by an elastic membrane 201 to form a valve chamber 218 in which a valve seat 225 is arranged, the front face of which faces the membrane and in the open position of the outlet valve is arranged at a distance from the valve seat, wherein a valve channel 240 passes through the valve seat. The outward flow path 223 comprises a first outward flow channel 214 which connects the outlet opening 216 of the pump chamber 252 to the outlet valve chamber 218, and a second outward flow channel 214A which connects the outlet valve chamber 240 to the exit connection 205, wherein the cross-section area of the outlet valve channel 240 is smaller than the cross-section area of the region of the valve chamber 218 surrounding the outlet valve seat 225.

Simple-to-use systems, methods, and devices for priming replacement blood treatment devices, for swapping the blood treatment devices out, for replacing swapped-out blood treatment devices, and other related operations are described. In embodiments, a blood treatment device can be primed while a therapy is still running. When the replacement blood treatment device is needed, the therapy can be stopped momentarily (less than a minute) for the rapid and safe swap of the blood treatment device. Blood loss can be minimized. The down time from therapy can be minimized.

The invention relates to extracorporeal blood circuits, and components thereof (e.g., hollow fiber membranes, potted bundles, and blood tubing), including 0.005% to 10% (w/w) surface modifying macromolecule. The extracorporeal blood circuits have an antithrombogenic surface and can be used in hemofiltration, hemodialysis, hemodiafiltration, hemoconcentration, blood oxygenation, and related uses.

A plasmapheresis system and a method for operating a plasmapheresis system are provided by which the reservoir for the concentrated red blood cells (RCC) has a first chamber for receiving anticoagulant used for priming the separator and purging the system of air prior to the initial draw cycle and a second chamber for receiving separated red blood cells. Because the entire volume of second chamber of the RCC reservoir may now receive separated red blood cells and no AC prime volume, a greater amount of whole blood may be processed in the first draw cycle, thus resulting in a greater total volume of Immunoglobulin G (IgG) being collected during the plasmapheresis procedure.

Dialysis systems are disclosed comprising new fluid flow circuits. Systems may include blood and dialysate flow paths, where the dialysate flow path includes balancing, mixing, and/or directing circuits. Dialysate preparation may be decoupled from patient dialysis. Circuits may be defined within one or more cassettes. The fluid circuit fluid flow paths may be isolated from electrical components. A gas supply in fluid communication with the dialysate flow path and/or the dialyzer able to urge dialysate through the dialyzer and urge blood back to the patient may be included for certain emergency situations. Fluid handling devices, such as pumps, valves, and mixers that to can be actuated using a control fluid may be included. Control fluid may be delivered by an external pump or other device, which may be detachable and/or generally rigid, optionally with a diaphragm dividing the device into first and second compartments.

A monitoring device operates to monitor regional citrate anticoagulation (RCA) in a blood treatment system which is configured to administrate citrate to an extracorporeal blood circuit (10) upstream of a dialyzer (11) during a treatment session. At consecutive time steps during the treatment session, the monitoring device obtains a current measurement value of systemic ionized calcium (iCa.sub.SYS) or systemic total calcium (Ca.sub.SYS), operates a predefined algorithm on the current measurement value to generate a current computation value that represents ionized calcium (iCa.sub.2, iCa.sub.3) in blood at a selected location (loc2, loc3) downstream or upstream of the dialyzer (11) in the extracorporeal blood circuit (10), and presents and/or evaluates the current computation value for assessment of the regional citrate anticoagulation. The need for conventional blood sampling and blood analysis upstream and/or downstream of the dialyzer, e.g. during CRRT, is thereby reduced significantly.

The invention relates to methods and systems for removal of pathogens from blood or blood products. The invention further relates to methods and systems for treatment and diagnosis of infection in the blood and/or sepsis in a patient in need thereof.

Systems and methods for cleansing blood are disclosed herein. The methods include acoustically separating target particles from elements of whole blood. The whole blood and capture particles are flowed through a microfluidic separation channel formed in a thermoplastic. At least one bulk acoustic transducer is attached to the microfluidic separation channel. A standing acoustic wave, imparted on the channel and its contents by the bulk acoustic transducer, drives the formed elements of the blood and target particles to specific aggregation axes.

A plasmapheresis system and a method for operating a plasmapheresis system are provided by which the volume/weight of anticoagulated plasma that is collected is optimized. In one example, a nomogram is provided that utilizes the donor's hematocrit to calculate the volume/weight of raw plasma within a plasma product having the maximum volume permitted by the FDA nomogram. In a plasmapheresis procedure having multiple collection phases followed by a reinfusion cycle in which concentrated red blood cells are returned to the donor, the volume of plasma product to be collected is calculated prior to the start of each collection cycle to account for the donor's increasing hematocrit, thus resulting in a greater total volume of plasma product to be collected during the plasmapheresis procedure.